SCHEMBL12479043

SCHEMBL12479043

CC(C)(C)OC(=O)n1nc(Br)c2ccc(C(=O)OCc3ccccc3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.43
▸ TDP1 Q9NUW8 4/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ JMJD6 Q6NYC1 1/20 0.42
▸ LMNA P02545 4/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ RAB9A P51151 7/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ NPC1 O15118 5/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAP2K4 P45985 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20488622 0.88 MAPT (0.43) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL29854924 0.88 MAPT (0.43) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL12480120 0.85 LMNA (0.43) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL12479865 0.82 SLC22A12 (0.39) LMNAMAP2K4
SCHEMBL7423685 0.77 JMJD6 (0.45) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL20487896 0.76 MAPT (0.42) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL2674135 0.76 MAP2K4 (0.44) L3MBTL1KMT2ARAB9AALDH1A1NPC1
SCHEMBL20489035 0.75 TDP1 (0.44) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL949890 0.74 JMJD6 (0.45) MAPTTDP1L3MBTL1JMJD6LMNA
SCHEMBL2861583 0.74 ELANE (0.42) MAPTRAB9ANPC1KDM4EMAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661433-B1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2017-08-16 — — EP disclosed
US-9085555-B2 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2015-07-21 — — US disclosed
EP-2661433-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) Novartis AG (CH) 2013-11-13 — — EP disclosed
US-20120295884-A1 Complement pathway modulators and uses thereof NOVARTIS AG (CH) 2012-11-22 — — US disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295884-A1 Complement pathway modulators and uses thereof C5, C3AR1, C9 MAPT 4024/4885TDP1 4428/4885L3MBTL1 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback